Adaptimmune Therapeutics PLC

ADAPY Healthcare Biotechnology

Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024. In the quarter to June 2025, revenue fell 89.3%, EPS fell 140.7% and free cash flow fell 174.7%, each against the same quarter a year earlier.

0.03 0.00 0.00%
Market cap
$14.6M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
4/9
Altman Z
−23.33
Beneish M
16.71
Dividend safety
n/a
Dec '25 Jun '25 Mar '25 Dec '24 Older periods
ROE
— (1,349.52%) 1,087.18% (273.57%)

+8 more TTM periods

Piotroski F-Score
— 0 2 4
ROA
0.00% (75.53%) (34.11%) (27.17%)
ROIC
— 0.00% 0.00% 0.00%
Return on Tangible Assets
— (311.98%) (86.91%) (46.83%)
Average Days of Receivables
— 52.23 8.90 29.49
Free Cash Flow per Share
— (0.71) (0.41) (0.28)
Free Cash Flow
— (187.58) (105.74) (71.02)
Other line items

Show all line items

Columns are period end dates